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Receptor for advanced glycation end products
High mobility group box 1
Host defensePneumonia caused by inﬂuenza A virus (IAV) can have devastating effects, resulting in respiratory failure and
death. The idea that a new inﬂuenza pandemic might occur in the near future has triggered renewed
interests in IAV infection. The receptor for advanced glycation end products (RAGE) is expressed on different
cell types and plays a key role in diverse inﬂammatory processes. We here investigated the role of RAGE in
the host response to IAV pneumonia using wild-type (wt) and RAGE deﬁcient (−/−) mice. Whereas strong
RAGE was constitutively expressed in the lungs of uninfected wt mice, in particular on endothelium, IAV
pneumonia was associated with enhanced expression on endothelium and de novo expression on bronchial
epithelium. Additionally, the high-afﬁnity RAGE ligand high mobility group box 1 was upregulated during IAV
pneumonia. RAGE−/− mice were relatively protected from IAV induced mortality and showed an improved
viral clearance and enhanced cellular T cell response and activation of neutrophils. These data suggest that
RAGE is detrimental during IAV pneumonia.© 2009 Elsevier Inc. All rights reserved.Introduction
Recent outbreaks of highly pathogenic inﬂuenza A virus (IAV)
infections have had important economic consequences and the notion
that a new inﬂuenza pandemic might occur in the near future has
triggered renewed interest in inﬂuenza infection. Inﬂuenza pneumo-
nia develops rapidly and can result in respiratory failure and death.
20,000 people die after inﬂuenza infection in the United States each
year and in the large pandemic of 1918, over 20 million people died
worldwide (Cheung et al., 2002; Palese, 2004). Three types of single
stranded RNA inﬂuenza viruses that can cause upper respiratory tractMedical Center, University of








ll rights reserved.infection have been described; A, B and C, of which inﬂuenza A is
clinically the most important (Wright and Webster, 2001). From a
preventive and treatment perspective, IAV is regarded as a problem
pathogen. Although vaccines and antiviral molecules to control IAV
have been developed recently, the disease is by no means under
control since these treatments are not available worldwide and their
efﬁcacy is not optimal (Kandel and Hartshorn, 2005; Palese, 2004;
Hayden, 2004). Moreover, the segmented genome of inﬂuenza virus is
subject to antigenic drift and shift, which may result in inﬂuenza
variants that are highly pathogenic for humans (De Jong et al., 2000).
Due to these genetic changes vaccine strategies and antiviral therapy
may become ineffective. Therefore, insight in factors involved in host
defense during IAV could help identify possible new preventive and/
or therapeutic targets in this severe infection.
The receptor for advanced glycation end products (RAGE) is a
promiscuous receptor that has been shown to be involved in
pulmonary inﬂammation and infection. RAGE can interact with
diverse ligands such as high mobility group box (HMGB)1 (Sorci
et al., 2004), somemembers of the S100 family; S100A12 (Moroz et al.,
2002), S100B (Valencia et al., 2004) and S100P (Arumugam et al.,
2004), advanced glycation end products (Kislinger et al., 1999),
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was ﬁrst identiﬁed in lung tissue (Schmidt et al., 1992) and endothelial
cells, alveolar and bronchial epithelial and plasmacytoid dendritic
cells have been found to express RAGE. Recent studies have conﬁrmed
that RAGE is extensively expressed in normal, healthy lungs and that
patients with interstitial and postobstructive pneumonia have an
increased pulmonary expression of RAGE (Morbini et al., 2006).
Recently, we demonstrated pulmonary RAGE upregulation in murine
pneumonia caused by Streptococcus (S.) pneumoniae (van Zoelen
et al., 2009).
Ligand binding to RAGE leads to sustained receptor-dependent
signaling and activation of nuclear factor-κB and mitogen-activated
protein kinase pathways. In line, inhibition of RAGE signaling has
been found to reduce inﬂammatory responses in several models,
including models of hepatic injury (Cataldegirmen et al., 2005; Zeng
et al., 2004; Ekong et al., 2006), diabetic atherosclerosis (Park et al.,
1998), type II collagen-induced arthritis (Hofmann et al., 2002) andFig. 1. Expression of pulmonary receptor for advanced glycation end products (RAGE) during
magniﬁcation, ×10) of lung tissue (A–D). Normal, uninfectedwild-type (wt) mouse (A) displ
Arrow indicates bronchial epithelium being negative for RAGE staining. Absence of RAGE p
inoculation of IAV (C and D). Arrow in C indicates bronchial epithelium being positive for RAG
for RAGE staining. Soluble (s)RAGE levels in bronchoalveolar lavage ﬂuid (BALF) from norm
bar, n=5–6 mice per group). ⁎⁎⁎Pb0.005, vs. healthy, uninfected mice (Mann–Whitney Usepsis (Liliensiek et al., 2004). Given the ubiquitous expression of
RAGE in the lung and its upregulation during inﬂammatory processes
and S. pneumoniae pneumonia, we hypothesized that this receptor
plays a role in the regulation of lung inﬂammation during viral
infection of the respiratory tract. Therefore, we here sought to
determine the role of RAGE in pneumonia caused by IAV. For this
RAGE deﬁcient (RAGE−/− mice) were intranasally infected with a
mouse adapted IAV and the course of the infection in these mice was
compared with that in concurrently infected wild-type (wt) mice.
Results
Inﬂuenza A pneumonia results in enhanced RAGE expression in the lungs
Earlier studies indicated that normal, healthy lungs express RAGE
(Cheng et al., 2005; Morbini et al., 2006; Uchida et al., 2006;
Wittkowski et al., 2007) and that expression of RAGE in the lungs isinﬂuenza A virus (IAV) pneumonia. Shown are representative RAGE stainings (original
aying extensive RAGE expression in the interalveolar septaewith an endothelial pattern.
ositivity in the lung of a RAGE−/− mouse (B). Lungs form a wt mouse 8 days after the
E staining (comparedwith A) and arrows in D indicate inﬂammatory cells being positive
al, uninfected wt mice (open bar) and from mice 8 days after IAV inoculation (E) (ﬁlled
test).
Fig. 3. (A) Receptor for advanced glycation end product deﬁcient (RAGE−/−) mice have
a prolonged survival during inﬂuenza A virus (IAV) pneumonia. Wild-type (wt; open
circles) and RAGE−/− (ﬁlled circles) mice (n=12–14 mice/genotype) received 200
TCID50 inﬂuenza virus intranasally on day 0. Mice were monitored at least twice a day
after inoculation. (B) Receptor for advanced glycation end product (RAGE) deﬁciency
diminishes viral load in the lungs. Viral load in lungs in wild-type (wt; open bars) and
RAGE deﬁcient (RAGE−/−; ﬁlled bars) mice at 4 and 8 days after 40 TCID50 intranasal
oculation with inﬂuenza A virus (IAV). Data are means±SEs (n=6–8 mice/genotype).
⁎Pb0.05, vs. wt mice (Kaplan–Meier analysis by log rank test).
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(Morbini et al., 2006). We recently demonstrated that RAGE is
upregulated during S. pneumoniae pneumonia (van Zoelen et al.,
2009). To study whether RAGE expression alters in our IAV
pneumonia model, we performed immunohistochemical stainings of
RAGE of lung tissue from wt mice after inoculation with IAV. In
accordance with the literature (Cheng et al., 2005; Morbini et al.,
2006; Uchida et al., 2006; Wittkowski et al., 2007), normal healthy
mice displayed broad RAGE staining in their lungs (Fig. 1A). RAGE was
predominantly present in the interalveolar septae, showing an
endothelial pattern, whereas RAGE was clearly absent in the bronchial
epithelium (Fig. 1A, arrow). Immunohistochemical analysis of lungs
obtained from RAGE−/− mice, used as negative controls, conﬁrmed
the speciﬁcity of the RAGE staining (Fig. 1B). Lungs from IAV infected
mice showed an upregulation of RAGE expression on endothelial cells
(Fig. 1C). Moreover, bronchial epithelial cells displayed de novo
expression of RAGE (Fig. 1C, arrow), as did some inﬂammatory cells
(Fig. 1D, arrows). In addition to immunohistochemistry, we measured
soluble (s)RAGE in bronchoalveolar lavage ﬂuid (BALF) from healthy
wt mice and mice inoculated with IAV. sRAGE levels increased after
IAV infection (Fig. 1E, Pb0.005).
HMGB1 is increased during inﬂuenza A virus pneumonia
After having shown that RAGE expression is enhanced during IAV
pneumonia, we next investigated whether IAV pneumonia is
associated with release of its high-afﬁnity ligand HMGB1 (Sorci
et al., 2004). We previously demonstrated increased HMGB1
concentrations in BALF from the infected site of patients with
pneumonia (van Zoelen et al., 2007), with S. pneumoniae being
isolated in 3 out of 4 cases. Relative to healthy controls, mice with
pneumonia induced by IAV had elevated HMGB1 levels in BALF at day
4 and day 8 (Fig. 2, Pb0.01 at day 8), the former time point not being
statistically signiﬁcant using a small number of mice.
RAGE−/−mice demonstrate a delayed mortality after infection with high
dose inﬂuenza A
To obtain a ﬁrst insight in the role of RAGE in the host response to
severe inﬂuenza infection, RAGE−/− and wt mice were intranasally
infected with 200 TCID50 IAV and followed for 10 days (Fig. 3A). This
viral dose was uniformly lethal in all mice. However, mortality was
signiﬁcantly delayed in RAGE−/− mice (P=0.0009 vs. wt mice).
Indeed, at day 6.5 post infection already 50% of wt mice had
succumbed, whereas at this time point all RAGE−/− mice were still
alive. At day 7.5 after infection 93% of the wt mice vs. only 67% of
RAGE−/−micewere dead. Hence, RAGE deﬁciency is associatedwith a
relative protection against inﬂuenza induced lethality.Fig. 2. High mobility group box (HMGB)1 levels in bronchoalveolar lavage ﬂuid (BALF)
from normal, uninfectedwtmice (open bar) and frommice 4 and 8 days after inﬂuenza
A virus inoculation (ﬁlled bars, n=4–6 mice per group). ⁎⁎Pb0.01, vs. healthy,
uninfected mice (Mann–Whitney U test).RAGE−/− mice have a reduced viral load 8 days after infection with
lower dose inﬂuenza A
To obtain insight into the role of RAGE in the clearance of IAV from
the lungs, wt and RAGE−/− mice were intranasally infected with a
lower dose (40 TCID50) to avoid bias due to the accelerated mortality
of wt mice and viral loads were determined in lung homogenates
obtained 4 and 8 days post infection (Fig. 3B). At day 4, viral loads
were similar in the lungs of wt and RAGE−/− mice. At day 8, the
number of viral copies had decreased in both mouse strains, but
signiﬁcantly more in RAGE−/−mice (Pb0.05 vs.wtmice). Thus, RAGE
deﬁciency is associated with an increased clearance of inﬂuenza A
from the respiratory tract.
RAGE−/− mice demonstrate more activation of CD4+ and CD8+ T cells
in lung inﬁltrates
To obtain insight into the role of RAGE in the lung inﬂammatory
response during inﬂuenza infection, lungs were harvested from wt
and RAGE−/− mice 8 days after inoculation for histopathology. Both
mouse strains showed extensive inﬂammation characterized by
severe bronchitis, alveolar inﬂammation and edema (Figs. 4A and B
show representative slides of wt and RAGE−/− mice, respectively).
The extent of lung inﬂammation, as determined by the semi-
quantitative histology score described in the Materials and methods
section, did not differ between wt and RAGE−/− mice (Fig. 4C). Next
we compared the cellular composition of pulmonary inﬁltrates at day
8 by ﬂow cytometry analysis. The percentages of CD4+ and CD8+
T cells, which both are considered important for host defense against
inﬂuenza infection, were similar in wt and RAGE−/− mice (Figs. 5A
and C, respectively). Remarkably, however, RAGE−/−mice displayed a
Fig. 4. Lung histopathology. Shown are representative hematoxylin–eosin stainings
(original magniﬁcation, ×10) of lung tissue of wt (A) and receptor for advanced
glycation end product deﬁcient (RAGE−/−; B) mice obtained 8 days after inoculation
with inﬂuenza A virus (IAV). Total histology scores of the lungs were determined in wt
and RAGE−/− mice 8 days after inﬂuenza virus inoculation (C) as described in the
Materials and methods section. Data are means±SEs (n=8–9 mice/genotype).
⁎Pb0.05, vs. wt mice (Mann–Whitney U test).
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CD8+ T cells (Figs. 5B and D, both Pb0.01 vs. wt mice), indicating
that RAGE deﬁciency resulted in an enhanced activation of T cells in
infected lungs. Moreover, whereas the percentages of neutrophils
were similar in lungs of wt and RAGE−/− mice, pulmonary
neutrophils in RAGE−/− mice demonstrated a relatively enhanced
expression of the activation marker CD11b (Figs. 5E and F, Pb0.05 vs.
wt mice).
Cytokine and chemokine responses
To establish the contribution of RAGE to cytokine and chemokine
production during inﬂuenza, lung (left panels) and plasma (right
panels) concentrations of TNF-α, IFN-γ, IL-6, IL-10 and MCP-1 were
measured inwt and RAGE−/−mice 4 and 8 days after infection (Fig. 6).
Overall, the levels of these mediators did not differ between the two
mouse strains, with the exception of elevated lung IL-10 concentra-tions and reduced plasma TNF-α concentrations in RAGE−/− mice
relative towtmice at day 4 post infection (both Pb0.05). IL-10 was not
or barely detectable in plasma in both mouse strains.
Discussion
IAV is a common cause of upper respiratory tract infection and
pneumonia. Host defense against inﬂuenza pneumonia is orche-
strated by a complex interaction between immune cells and
regulatory cytokines. RAGE is a multiligand receptor of the immu-
noglobulin superfamily that is expressed in all tissues on awide range
of cell types, including cells involved in the innate immune system,
e.g. neutrophils, monocytes, macrophages, endothelial and plasmacy-
toid dendritic cells (Bierhaus et al., 2006; Dumitriu et al., 2005b,
2005a, 2007). Considering its ubiquitous expression in lungs and its
established role in inﬂammation, we here investigated the role of
RAGE during pulmonary infection with IAV. Our main ﬁnding is that
RAGE−/− mice had an increased resistance against inﬂuenza
pneumonia, as reﬂected by a delayed mortality associated with an
accelerated viral clearance from the lungs.
To the best of our knowledge only one study has been published
investigating the role of RAGE in pneumonia. We recently found that
RAGE deﬁciency is beneﬁcial during murine pneumonia induced by S.
pneumoniae (van Zoelen et al., 2009). In this report, RAGE−/− mice
had a better survival in combinationwith lower bacterial loads. Part of
these results could be explained by a better killing performance of S.
pneumoniae by RAGE−/−macrophages. This is the ﬁrst study focusing
on the role of RAGE in viral pneumonia.
Our data on expression of RAGE in the lungs extend earlier reports
in ﬁnding broad RAGE expression in normal, healthy lungs (Cheng
et al., 2005; Morbini et al., 2006; Uchida et al., 2006; Wittkowski et al.,
2007) and an upregulation of pulmonary RAGE expression during
interstitial and postobstructive pneumonia (Morbini et al., 2006; van
Zoelen et al., 2009). In two other studies it was found that full length
RAGE expression is not increased during lung inﬂammation. Acute
lung injury in rats induced by intratracheal instillation of LPS did not
alter the distribution of RAGE-expressing cells (Uchida et al., 2006).
Furthermore, patients with the acute respiratory distress syndrome
did not display an upregulation of RAGE expression (Wittkowski et al.,
2007). In the present study, we found that IAV pneumonia is
associated with an upregulation of RAGE expression on endothelial
cells and with de novo expression of RAGE on bronchial epithelial cells.
RAGE can interact with several different ligands such as HMGB1
(Hori et al., 1995; Sorci et al., 2004), advanced glycation end products
(Kislinger et al., 1999), amyloid (Yan et al., 2000), β-sheet ﬁbrils (Yan
et al., 1996) and some members of the S100 family (Valencia et al.,
2004; Arumugam et al., 2004; Moroz et al., 2002). From these ligands,
HMGB1 and S100 family members are likely to be released during
pneumonia. We here showed that HMGB1 levels are elevated in BALF
during IAV pneumonia. From the S100 family members, deﬁnitive
evidence for binding to RAGE has been deduced for S100A12, S100B
and S100P (Valencia et al., 2004; Arumugam et al., 2004; Moroz et al.,
2002). Evidence that a functional S100A12 gene is not present in the
murine genome (Fuellen et al., 2003) implies that RAGE-S100A12
ligation does not attribute to the host response to pneumonia in mice.
Until now, there are no data suggesting that S100B and S100P are
likely to play an important in pneumonia. By far the brain is the richest
source of S100B, and astrocytes represent the cell type with the
highest expression. S100P, initially identiﬁed in placenta, is expressed
in a number of cells and tissues and is signiﬁcantly upregulated in
highly metastatic cancer cells suggesting an involvement in tumor cell
migration. Nevertheless, future research is warranted to investigate
whether RAGE-S100B and/or RAGE-S100P ligation play a role during
pneumonia and other infectious diseases. In addition, it would be of
interest to study the possible therapeutic effects of RAGE (ligand)
inhibitors in IAV pneumonia.
Fig. 5. Receptor for advanced glycation end product deﬁcient (RAGE−/−) mice show enhanced activation of pulmonary T lymphocytes and neutrophils. Wild-type (wt) and RAGE−/−
micewere intranasally inoculated with inﬂuenza Avirus (IAV). After 8 days, lung cell suspensions were collected and ﬂowcytometrywas performed as described in theMaterials and
methods section. Results are represented as percentage of CD4+ (A), CD8+ (C) cells and neutrophils (E) in the lungs and as the mean ﬂuorescence intensity of CD69 surface
expression within the CD4+ (B) and CD8+ (D) population and of CD11b surface expression within the Gr1+ population (F). Data are means±SEs of 8–9 mice/genotype. ⁎Pb0.05,
vs. wt mice. ⁎⁎Pb0.01, vs. wt mice. ⁎⁎⁎Pb0.005, vs. wt mice (Mann–Whitney U test).
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immune cells during viral airway infection. Both CD4+ and CD8+ T
cells have been implicated in host defense against IAV. The CD4+Tcell
subset has been suggested to be the primary inducer of inﬂammatory
processes during IAV infection. However, depletion of CD4+ T cells in
normal mice had little effect on the clearance of IAV or the cell
composition and the localization of CD8+ T cells in the lungs of mice
(Allan et al., 1990). In contrast, depletion of CD8+ Tcells did affect IAV
titers in the lungs. Therefore, CD8+ T cells are regarded as primary
effector cells involved in the clearance of IAV (Eichelberger et al., 1991;
Scherle et al., 1992). In our study, the RAGE−/− mice did not show
differences in the number of either CD4+ or CD8+ cells. However, the
cellular immune response against IAV infection was enhanced in the
RAGE−/− mice, as reﬂected by a higher expression of CD69 on the
surface of the CD4+ and CD8+ T lymphocytes when compared with
wt mice. Furthermore, pulmonary neutrophils from RAGE−/− mice
displayed an increased capacity to upregulate their CD11b expression
during IAV. These data indicate that the improved survival and lower
viral loads at 8 days after inoculationwith IAV could at least partially be
explainedbyan increased activation status of CD4+, CD8+Tcells and/
or neutrophils (neutrophils see also further).In addition to an increased activation of CD4+ and CD8+ T cells,
we also found that RAGE deﬁciency is associated with an enhanced
capacity to upregulate CD11b on neutrophils. Neutrophils may play a
direct role in viral clearance. First of all, they are recruited to the
respiratory tract early in the course of IAV infection (White et al.,
2007; LeVine et al., 2001; Sakai et al., 2000; Sweet and Smith, 1980)
and they can bind to and take up IAV (Hartshorn et al., 1990, 1995).
Furthermore, IAV stimulates various activation signals and H2O2
generation by neutrophils (Hartshorn et al., 1990, 1995). Previously it
has been shown that (immature) Gr1+ CD11b+ cells are responsible
for augmentation of the Th2 cell-dependent and depression of Th1
cell-dependent responses during severe infection (sepsis) (Delano
et al., 2007). In general this phenomenon is associated with sepsis-
associated morbidity and worsened outcome. Data about this
myeloid-derived suppressor cell-induced Th shift during IAV pneu-
monia are lacking. In our model we did ﬁnd enhanced CD11b
expression on Gr1+ cells and higher IL-10 levels in the lungs of the
RAGE−/− mice. However, it remains to be elucidated whether this is
due to a Th shift. The Gr1+ CD11b+ cells in our lung cell suspensions
could very well be mature neutrophils originating from the blood
being inﬁltrated into the lungs. In addition, in sepsis, this shift is
Fig. 6. Pulmonary and plasma cytokine concentrations. Cytokine levels in lungs (left panels) and plasma (right panels) from wild-type (wt; open bars) and receptor for advanced
glycation end product deﬁcient (RAGE−/−; ﬁlled bars) mice 4 and 8 days after inoculation with inﬂuenza A virus (IAV). Data are means±SEs (n=6–8 mice/genotype). ⁎Pb0.05, vs.
wt mice.
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our inﬂuenza model the elevated CD11b expression is associated with
decreased mortality. Therefore, future studies should indicate
whether this phenomenon is induced during IAV infection and
whether it can be of beneﬁt for the host.
Our data point towards an adverse effect of RAGE on viral
clearance, activation of CD4+ and CD8+ T cells and mortality during
IAV infection. The underlying mechanism of RAGE-mediated immu-
nosuppression is unclear. Previously, Dumitriu et al. (2005b, 2005a,
2007) found that RAGE mediates the maturation of plasmacytoid
dendritic cells (pDCs) through autocrine release of HMGB1. Antigen
presentation by pDC is associated with immunotolerance and may
explain the adverse effect of RAGE on T cell activation (de Heer et al.,
2004; Derks et al., 2007). However, the contribution of pDCs during
viral infection is largely unknown. In addition, HMGB1 and RAGE have
also been implicated in the maturation of monocyte-derived dendritic
cells (Yang et al., 2007). Further research is required to identify the
role of RAGE and/or HMGB1 in DC maturation during viral airway
infection.
Summarized, our data suggest that RAGE−/− mice have an
improved host defense during IAV pneumonia, possibly by an
increased activation of pulmonary neutrophils and thereby a better
antiviral clearance.
Considering the role of HMGB1 and RAGE in the maturation of
pDCs, the observed effects in the RAGE−/− mice could at least be
partly explained by interaction of HMGB1 with RAGE. Of note,
negative-stranded RNA viruses such as RSV and Sendai virus have
been shown to induce maturation of pDCs (Hornung et al., 2004). In
addition to HMGB1, advanced glycation end products (AGEs) –
another group of known RAGE ligands – could also play a role during
IAV infection; IAV infection is associated with the production of pro-
inﬂammatory cytokines and the recruitment of inﬂammatory cells of
the innate and adaptive immune system, which contribute to
oxidative stress (Han and Meydani, 2000; Peterhans, 1997) and may
give rise to the formation of AGEs. Further research is warranted to
address the individual contribution of these RAGE ligands.
Cytokines play an important role in the host defense during IAV
infection via e.g. activation of T cells or via their more direct antiviral
properties. IFN-γ plays an important role in the antiviral host defense
at least in part by its promotion of the activation of CD8+ cells, which
are responsible for speciﬁc lysis of virus-infected cells (Micallef et al.,
1996; Gherardi et al., 2003; Nguyen et al., 1998). In addition, its
involvement in the antiviral immune defense is suggested by the
ﬁnding that several viruses encode proteins designed to interfere
with IFN-γ signaling (Alcami and Smith, 1996). Other cytokines such
as TNF-α, IL-6, IL-10 and MCP-1 are released during IAV as well
(Dessing et al., 2007). To determine whether the delayed mortality
and the reduced viral load at 8 days after inoculation could (at least
partially) be due to an altered release of cytokines, we measured
IFN-γ, TNF-α, IL-6, IL-10 and MCP-1. There were no differences in
cytokines between the two mouse strains, except for lower plasma
levels of TNF-α at 4 days and elevated IL-10 levels at 8 days after
inoculation in the RAGE−/−mice. These data suggest that the delayed
mortality and the increased clearance of the viral load were not likely
the consequence of an effect of RAGE deﬁciency on IAV induced
cytokine production.
Our key ﬁnding was that RAGE deﬁciency enhances the resistance
against IAV pneumonia as reﬂected by an increased survival and an
enhanced viral clearance. The current study is the ﬁrst to establish that
RAGE plays a detrimental role in the antiviral defense against IAV. The
delayed mortality and decreased viral loads in the RAGE−/− mice
were associated with an enhanced cellular T cell response, implicating
that endogenous RAGE impairs the cellular immunity against
respiratory tract infection with IAV. Hence, these data suggest that
along with inhibitors of viral replication, RAGE inhibitors might be
useful in the management of severe IAV infection.Materials and methods
Mice
Pathogen-free 8 to 10 week old female wt C57Bl/6 mice were
purchased from Harlan Sprague Dawley Inc. (Horst, The Netherlands).
RAGE−/−mice, backcrossed ten times to a C57Bl/6 background, were
generated as described previously (Liliensiek et al., 2004). The
Institutional Animal Care and Use Committee of the AcademicMedical
Center, University of Amsterdam, approved all experiments.
Experimental infection
Inﬂuenza infection was induced as described previously using
inﬂuenza A strain A/PR/8/34 (ATCC no. VR-95; Rockville, MD) (Keller
et al., 2006). Mice were anesthetized by inhalation with isoﬂurane
(Abott Laboratories Ltd., Kent, UnitedKingdom) and infected intranasally
with 40 TCID50 (5600 viral copies) inﬂuenza A in 50 μl PBS. After 4 or
8 days, mice were anesthetized with ketamine (Eurovet Animal Health
BV, Bladel, The Netherlands) and medetomidine (Pﬁzer Animal Health
BV, Capelle aan de IJssel, The Netherlands) and killed for the measure-
ments described below. Additionally, in a separate survival study mice
were infected with 200 TCID50 (28,000 viral copies) inﬂuenza A.
Preparation of blood samples and lung homogenates
Blood was collected by heart puncture in heparin containing tubes
and centrifuged at 1500 ×g for 10 min, after which plasma was
collected and frozen at −20 °C until assayed. Lungs were harvested
and weighed to obtain relative organ weight. Additionally, lungs were
homogenized at 4 °C in 4 volumes of sterile isotonic salinewith a tissue
homogenizer (Biospect Products, Bartlesville, OK) whichwas carefully
cleaned and disinfected with 70% ethanol after each homogenization.
Lung homogenates were lysed in 1 volume of lysis buffer (300 mM
NaCl, 15 mM Tris [tris(hydroxymethyl)aminomethane], 2 mM MgCl2,
2 mM Triton X-100, pepstatin A, leupeptin and aprotinine [20 ng/ml],
pH 7.4) on ice for 30min and centrifuged at 1500 ×g at 4 °C for 10min.
The supernatants were frozen at−20 °C until assayed.
Bronchoalveolar lavage
In separate mice, not used for pathology or preparation of lung
homogenates, BALF was obtained and differential counts were carried
out as described earlier (Rijneveld et al., 2001). Brieﬂy, the trachea
was exposed through a midline incision and BALF was harvested by
instilling and retrieving two 0.5-ml aliquots of sterile isotonic saline.
Cell counts were determined using an automated counter (Beckham
Coulter, Coulter ZF, Mijdrecht, The Netherlands).
Assays
Viral loadwas determined using real-time quantitative PCR exactly
as described (Keller et al., 2006; Dessing et al., 2007). Tumor necrosis
factor (TNF)-α, interferon-gamma (IFN-γ), interleukin (IL)-6, IL-10
and monocyte chemoattractant protein (MCP)-1 levels were deter-
mined using a cytometric beads array (CBA) multiplex assay (BD
Biosciences, San Jose, CA) in accordance with the manufacturer's
recommendations. sRAGE levels were measured by ELISA (R&D,
Minneapolis, MN, USA) as described before (Kalea et al., 2009).
HMGB1 was measured by Western immunoblotting as described
before (Wang et al., 1999; Yang et al., 2004).
Histology
Lungs for histologic examinationwere harvested after 8 days, ﬁxed
in 4% formaldehyde, embedded in parafﬁn and cut in 4-μm thick
272 M.A.D. van Zoelen et al. / Virology 391 (2009) 265–273sections for staining procedures. Immunostaining for RAGE was
performed on parafﬁn slides after deparafﬁnization and rehydration
using standard procedures. Endogenous peroxidase activity was
quenched using 1.5% H2O2 in PBS. Primary antibodies used were
goat anti-mouse RAGE polyclonal antibodies (Neuromics, Edina, MN)
and secondary antibodies were biotinlylated rabbit anti-goat anti-
bodies (DakoCytomation, Glostrup, Denmark). ABC solution (Dako-
Cytomation, Glostrup, Denmark) was used as the detection enyzme.
DAB peroxidase (Sigma, St. Louis, MO) was used as substrate for
visualization. Counterstaining was performed with methylgreen
(Sigma Aldrich, St. Louis, MO). Hematoxylin–eosin stainings were
performed as described (Leemans et al., 2002) and analyzed by a
pathologist who had no knowledge of the genotype of the mice. To
score lung inﬂammation and damage, the lung samples were screened
for the following parameters: interstitial inﬂammation, alveolar
inﬂammation, vasculitis, bronchitis, edema, and pleuritis. Each
parameter was graded on a scale of 0 to 4 (0, absent; 1, very mild; 2,
mild; 3, moderate; and 4, severe). The total “lung inﬂammation score”
was expressed as the sum of the scores for each parameter, the
maximum being 24 (Leemans et al., 2002).
Flow cytometry
Lung cell suspensions were obtained from infected mice by
grinding lung tissue through nylon sieves and analyzed by ﬂow
cytometry using FACSCalibur (Becton Dickinson Immunocytometry
Systems, San Jose, CA) in essence as described previously (Dessing
et al., 2007). Cells were brought to a concentration of 4×106/ml in
FACS buffer (PBS supplemented with 0.5% BSA, 0.01% NaN3 and
0.35 mM EDTA). Immunostaining of cell surface molecules was
performed for 30 min and 4 °C with anti-CD4-allophycocyanin (APC),
anti-CD8-peridinin chlorophyl protein (PerCP), anti-CD3-biotin, anti-
CD69-phycoerythrin (PE), anti-Gr1-phycoerythrin (PE, clone RB6-
8C5) and anti-CD11b-allophycocyanin (APC). All antibodies were from
the same manufacturer (BD Pharmingen, San Diego, CA) and used in
concentrations recommended. CD69 surface molecules were analyzed
on CD3+ cells within the lymphocyte gate and CD11b on Gr1+ cells.
Statistical analysis
All values are expressed as means±SEs. Comparisons were done
with Mann–Whitney U tests. Survival curves were compared by log
rank test. Values of Pb0.05 were considered statistically signiﬁcant.
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